Company Description
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea.
The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.
The company’s products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs.
It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea.
In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea.
The company is headquartered in San Francisco, California.
| Country | United States |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 49 |
| CEO | Ms. Lisa A. Conte |
Contact Details
Address: 200 Pine Street Suite 400 San Francisco, California 94104 United States | |
| Phone | 415-371-8300 |
| Website | jaguar.health |
Stock Details
| Ticker Symbol | JAGX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001585608 |
| CUSIP Number | 47010C607 |
| ISIN Number | US47010C7065 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Lisa A. Conte | Founder, Chief Executive Officer, President and Director |
| Dr. Pravin R. Chaturvedi Ph.D. | Chief Scientific Officer and Chair of Scientific Advisory Board |
| Jonathan S. Wolin CPA, J.D., M.B.A. | Chief of Staff, Chief Compliance Officer and General Counsel |
| Ian H. Wendt M.B.A. | Chief Commercial Officer |
| Dr. Steven R. King Ph.D. | Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property and Secretary |
| Carol R. Lizak M.B.A. | Chief Financial Officer |
| Peter Hodge | Senior Director of Investor Relations, Business Development and Special Events |
| Dr. Karen J. Brunke Ph.D. | Executive Vice President of Corporate and Business Development |
| David Sesin | Chief Manufacturing Officer |
| Dr. Massimo Radaelli M.B.A., Ph.D. | President of Jaguar International |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 18, 2024 | 8-K | Current Report |
| Jul 18, 2024 | 424B5 | Filing |
| Jul 16, 2024 | 8-K | Current Report |
| Jun 26, 2024 | 8-K | Current Report |
| Jun 21, 2024 | 8-K | Current Report |
| Jun 10, 2024 | 8-K | Current Report |
| Jun 10, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| May 31, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 28, 2024 | ARS | Filing |
| May 23, 2024 | 8-K | Current Report |